Division of Surgical Oncology and Thoracic Surgery, Oncology and Palliative Care, Helios Medical Centre, Bad Saarow, Germany.
Br J Surg. 2010 Dec;97(12):1854-9. doi: 10.1002/bjs.7222. Epub 2010 Aug 20.
This study assessed the outcomes of patients with a gastrointestinal stromal tumour (GIST) that ruptured before or during resection.
The records of 23 patients (8 women, 15 men; median age 54 years) with ruptured primary non-metastatic GIST were retrieved from a database of 554 patients. The written surgical and pathology reports were analysed. Review pathology was performed in all 23 cases, and mutational analysis of KIT and platelet-derived growth factor α (PDGFRA) genes was performed in 21 patients. Median follow-up was 52 months.
Tumour rupture was spontaneous in 16 patients, following abdominal trauma in two and occurred during resection in five. Primary tumour location was the stomach in six patients, duodenum in one and small bowel in 16. Mean tumour size was 10·2 (range 4-28) cm. According to the Miettinen and Lasota risk classification, the distribution of very low-, low-, intermediate- and high-risk cases was one, two, five and 15 respectively. One patient remained disease-free at 83 months. Fifteen of 16 patients who did not receive adjuvant therapy developed tumour recurrence after a median of 19 months. Median recurrence-free survival in patients with KIT mutations involving codons 557-558 was 11 months.
Patients with a rupture of GIST into the abdominal cavity have a risk of recurrence of nearly 100 per cent. In patients with deletion mutations involving codons 557-558, recurrence-free survival was less than 1 year. All patient groups are clear candidates for adjuvant drug therapy.
本研究评估了胃肠道间质瘤(GIST)在切除前或切除过程中破裂患者的结局。
从 554 例患者的数据库中检索出 23 例(8 名女性,15 名男性;中位年龄 54 岁)原发性非转移性 GIST 破裂患者的记录。分析书面手术和病理报告。对所有 23 例患者进行了复查病理检查,并对 21 例患者进行了 KIT 和血小板衍生生长因子α(PDGFRA)基因突变分析。中位随访时间为 52 个月。
16 例患者的肿瘤破裂是自发性的,2 例患者因腹部外伤,5 例患者在切除过程中发生破裂。原发肿瘤部位在胃的有 6 例,十二指肠 1 例,小肠 16 例。肿瘤平均大小为 10.2(4-28)cm。根据 Miettinen 和 Lasota 风险分类,极低危、低危、中危和高危病例的分布分别为 1、2、5 和 15 例。1 例患者在 83 个月时仍无疾病。16 例未接受辅助治疗的患者中有 15 例在中位时间 19 个月后发生肿瘤复发。KIT 突变涉及密码子 557-558 的患者无复发生存期为 11 个月。
GIST 破裂进入腹腔的患者复发风险接近 100%。涉及密码子 557-558 缺失突变的患者,无复发生存期小于 1 年。所有患者均为辅助药物治疗的明确候选者。